I am issuing a call to action to the FDA, to industry, and to all Members of Congress, but most especially our committee, to take these problems seriously and work together on a bipartisan basis to address them.
Eshoo emphasizes the need for bipartisan action to address drug supply issues.
Share
More from Anna Eshoo
I've long been a champion for protecting vulnerable communities from the harms that come with new technologies.
I rise, sadly, in opposition to this bill, H.R. 485. I support, and everyone here supports, banning quality-adjusted life years, also known as QALYs. It is a discriminatory metric that should not be used, and Democrats are the ones who…
I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.
I thank the ranking member of the full committee for yielding time. Today, the House is going to vote on my legislation, H.R. 3226, the PREEMIE Reauthorization Act. I thank the co-leads of this legislation: Representatives Miller-Meeks…
Other voices in this conversation
